JP Morgan Chase’s Zhengye Biotechnology Holding ZYBT Stock Holding History

JP Morgan Chase’s Portfolio ZYBT Stock Details ZYBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-134	Closed	-$93	–	8627
2026 Q2	$93	Buy	+134	New	+$120	﹤0.01%	7543
2026 Q1	–	Sell	-457	Closed	-$526	–	8019
2025 Q4	$526	Buy	+457	New	+$1.01K	﹤0.01%	7078

Other funds holding ZYBT

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

JP Morgan Chase's ZYBT Position: Q3 2026 in Review

JP Morgan Chase sold out of Zhengye Biotechnology Holding (ZYBT) in Q3 2026, closing a stake of 134 shares — an estimated $93 sold.

JP Morgan Chase first reported a position in ZYBT in Q4 2025 and held it in 2 quarters. The position peaked at $526 in Q4 2025. 4 funds tracked by Wall St. Rank hold ZYBT as of Q3 2026.

JP Morgan Chase reported no remaining Zhengye Biotechnology Holding position as of Q3 2026 after selling out during the quarter.
JP Morgan Chase sold 134 Zhengye Biotechnology Holding shares in Q3 2026, an estimated $93.
JP Morgan Chase first reported a position in Zhengye Biotechnology Holding in Q4 2025 and held it in 2 quarters.
JP Morgan Chase's Zhengye Biotechnology Holding position peaked at $526 in Q4 2025.
4 funds tracked by Wall St. Rank held Zhengye Biotechnology Holding as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.